NYSE:LLYPharmaceuticals
Evaluating Eli Lilly (LLY) After Foundayo’s Slow Start And Recent Share Price Weakness
Fresh prescription data for Eli Lilly (LLY) put its new oral GLP-1 pill Foundayo under the microscope, with early use lagging Novo Nordisk’s Wegovy and Zepbound scripts also softening and pressuring the stock.
See our latest analysis for Eli Lilly.
The stock has pulled back in recent weeks, with a 1 day share price return of 3.67% decline and a 90 day share price return of 16.82% decline, even as headlines focus on Foundayo’s slower start, Kelonia deal reports, and Lilly’s broader GLP 1 and...